Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in STEMI
NCT06174753Phase 3Recruiting
- Sponsor
- University of Ottawa Heart Institute
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dapagliflozin in ST elevation myocardial infarction (STEMI), sponsored by University of Ottawa Heart Institute. Started Jan 2025; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
ST elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06174753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06174753.